A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Cilofexor (Primary) ; Firsocostat (Primary) ; Semaglutide (Primary)
- Indications Liver cirrhosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms WAYFIND
- Sponsors Gilead Sciences
- 17 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2023 Results (n=166) assessing Utility of SomaSignalTM panels for drug response and monitoring disease progression in patients with advanced fibrosis due to non- alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023
- 28 Mar 2023 Planned End Date changed from 1 Mar 2024 to 1 Dec 2024.